Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection

• Status: Unknown status
• Trial end date: 2018-11-01
• Target enrollment: 0
• Participant gender: Male

Summary

Pilot study to evaluate the impact of extremely early ART in the dynamics of viral reservoir, immune activation and inflammation in patients with HIV-1 infection of less than 20 days (Fiebig stages I-II) compared to patients with infection of 20-100 days (Fiebig stages III-V), to induce HIV functional cure.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: David Garcia Cinca
• Collaborator: Fundacion Clinic per a la Recerca Biomédica
• Treatments: Anti-Retroviral Agents

Criteria

Inclusion Criteria:

• Men who have sex with men

• Male's between18 and 65 years old

• Less than 100 days of infection

• Patient stage Fiebig I to V

• Negative or Incomplete western blot with negative p31 band

Exclusion Criteria:

• P31 positive band in western blot

• Positive Delta32 CCR5 mutation, HLA-B5701 or HLA-B27 (´late' exclusion criteria)

• Active oncological disease

• Active hepatitis C virus infection